Congressional dissatisfaction with FDA’s approach to guidance development reached a boiling point April 30, with eight Republican senators stating that finalizing biosimilar guidance may have in fact have made the agency’s policy position less certain.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?